Sun Y-M, Wang W-T, Zeng Z-C, Chen T-Q, Han C, Pan Q, et al. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression. Blood. 2019;134:1533–46.

CAS  PubMed  PubMed Central  Google Scholar 

Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.

CAS  PubMed  Google Scholar 

Oñate G, Pratcorona M, Garrido A, Artigas-Baleri A, Bataller A, Tormo M, et al. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer J. 2023;13:69.

PubMed  PubMed Central  Google Scholar 

Majothi S, Adams D, Loke J, Stevens SP, Wheatley K, Wilson JS. FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis. Syst Rev. 2020;9:285.

CAS  PubMed  PubMed Central  Google Scholar 

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728–40.

CAS  PubMed  Google Scholar 

Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984–97.

CAS  PubMed  Google Scholar 

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64.

CAS  PubMed  PubMed Central  Google Scholar 

Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6:2144–55.

CAS  PubMed  PubMed Central  Google Scholar 

Chang E, Ganguly S, Rajkhowa T, Gocke CD, Levis M, Konig H. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia. 2016;30:1025–32.

CAS  PubMed  Google Scholar 

Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121:4655–62.

CAS  PubMed  PubMed Central  Google Scholar 

Al-Jamal HAN, Mat Jusoh SA, Hassan R, Johan MF. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. BMC Cancer. 2015;15:869.

PubMed  PubMed Central  Google Scholar 

Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2012;130:1715–25.

CAS  PubMed  Google Scholar 

Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120:513–22.

CAS  PubMed  Google Scholar 

Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15:397–408.

CAS  PubMed  Google Scholar 

Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, et al. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood. 1995;85:657–63.

CAS  PubMed  Google Scholar 

Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845–59.

CAS  PubMed  Google Scholar 

Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol J Am Soc Clin Oncol. 1998;16:1197–206.

CAS  Google Scholar 

Gündogdu MS, Liu H, Metzdorf D, Hildebrand D, Aigner M, Aktories K, et al. The haematopoietic GTPase RhoH modulates IL3 signalling through regulation of STAT activity and IL3 receptor expression. Mol Cancer. 2010;9:225.

PubMed  PubMed Central  Google Scholar 

Terada K, Kaziro Y, Satoh T. Ras is not required for the interleukin 3-induced proliferation of a mouse pro-B cell line, BaF3. J Biol Chem. 1995;270:27880–6.

CAS  PubMed  Google Scholar 

Shibayama H, Anzai N, Braun SE, Fukuda S, Mantel C, Broxmeyer HE. H-Ras is involved in the inside-out signaling pathway of interleukin-3-induced integrin activation. Blood. 1999;93:1540–8.

CAS  PubMed  Google Scholar 

Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–12.

CAS  PubMed  Google Scholar 

Lv K, Ren J-G, Han X, Gui J, Gong C, Tong W. Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression. Blood. 2021;138:2244–55.

CAS  PubMed  PubMed Central  Google Scholar 

Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood. 2016;127:2214–8.

CAS  PubMed  Google Scholar 

Cabezas-Wallscheid N, Klimmeck D, Hansson J, Lipka DB, Reyes A, Wang Q, et al. Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell. 2014;15:507–22.

CAS  PubMed  Google Scholar 

Rong Q-X, Wang F, Guo Z-X, Hu Y, An S-N, Luo M, et al. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma. Mol Cancer. 2021;20:80.

CAS  PubMed  PubMed Central  Google Scholar 

Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, et al. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia. J Clin Invest. 2024;134:e168536.

CAS  PubMed  PubMed Central  Google Scholar 

Pan Y-M, Wang C-G, Zhu M, Xing R, Cui J-T, Li W-M, et al. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol Cancer. 2016;15:79.

PubMed  PubMed Central  Google Scholar 

Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, et al. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res J Am Assoc Cancer Res. 2014;20:3849–61.

CAS  Google Scholar 

Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, et al. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica. 2020;105:435–47.

CAS  PubMed  PubMed Central  Google Scholar 

Cortes J. Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. J Hematol Oncol J Hematol Oncol. 2024;17:111.

CAS  PubMed  Google Scholar 

Di Micco R, Krizhanovsky V, Baker D, d’Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol. 2021;22:75–95.

PubMed  Google Scholar 

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013;122:3607–15.

CAS  PubMed  PubMed Central  Google Scholar 

Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10:1028–35.

CAS  PubMed  PubMed Central  Google Scholar